<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684940</url>
  </required_header>
  <id_info>
    <org_study_id>BMN 270-205</org_study_id>
    <secondary_id>2019-003213-34</secondary_id>
    <nct_id>NCT04684940</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors</brief_title>
  <official_title>A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Active or Prior Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I/II clinical study will evaluate the safety and efficacy of valoctocogene&#xD;
      roxaparvovec in patients with severe haemophilia A and inhibitors to FVIII. Part A of the&#xD;
      study will involve subjects who have active inhibitors to FVIII, and Part B involving&#xD;
      subjects with a prior history of inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2027</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 after administration of BMN 270.</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the median Factor VIII activity.</measure>
    <time_frame>60 months</time_frame>
    <description>Changes in the median Factor VIII activity (IU/mL) after administration of BMN 270 which will be measured using the chromogenic FVIII assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A decrease in Factor VIII inhibitor titer (Part A) after administration of BMN 270.</measure>
    <time_frame>60 months</time_frame>
    <description>FVIII inhibitor titer will be measured using a chromogenic Nijmegen-Bethesda assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of recurrence of Factor VIII inhibitors (Part B) after administration of BMN 270.</measure>
    <time_frame>60 months</time_frame>
    <description>FVIII inhibitor titer will be measured using a chromogenic Nijmegen-Bethesda assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the annualized utilization (IU/kg) of emicizumab and exogenous FVIII replacement therapy for subjects receiving emicizumab or FVIII prophylaxis respectively after administration of BMN 270.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the annualized number of bleeding episodes requiring exogenous emicizumab or FVIII replacement treatment after administration of BMN 270.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemophilia A With Inhibitor</condition>
  <condition>Hemophilia A With Anti Factor VIII</condition>
  <arm_group>
    <arm_group_label>Valoctocogene roxaparvovec Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg in Active Inhibitor Population (Part A) and Prior Inhibitor Population (Part B).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Valoctocogene roxaparvovec</intervention_name>
    <description>Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A</description>
    <arm_group_label>Valoctocogene roxaparvovec Open Label</arm_group_label>
    <other_name>BMN 270</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males ≥ 18 years of age with hemophilia A and documented prior residual FVIII activity&#xD;
             ≤ 1 IU/dL including, but not limited to, at the time of detected inhibitors, at the&#xD;
             time of signing the informed consent.&#xD;
&#xD;
          2. History of a positive inhibitor result with the first positive result in the last 12&#xD;
             months.&#xD;
&#xD;
             Part A: Positive FVIII inhibitor titer ≥ 0.6 BU. Part B: Negative FVIII inhibitor&#xD;
             screening titer &lt; 0.6 BU.&#xD;
&#xD;
          3. Part A: Emicizumab prophylaxis at least 6 months prior to screening; Part B: FVIII&#xD;
             replacement prophylaxis for 12 months. Bleeding, inhibitor &amp; hemophilia therapy Hx&#xD;
             over previous 12 months.&#xD;
&#xD;
          4. Sexually active participants must agree to use an acceptable method of effective&#xD;
             contraception. Participants must agree to contraception use for at least 12 weeks&#xD;
             post-infusion.&#xD;
&#xD;
          5. Willing to abstain from consumption of alcohol for at least the first 52 weeks&#xD;
             following BMN 270 infusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Detectable pre-existing antibodies to the AAV5 capsid.&#xD;
&#xD;
          2. Any evidence of active infection or any immunosuppressive disorder; patients with HIV&#xD;
             infection and undetectable viral load are not excluded.&#xD;
&#xD;
          3. Currently undergoing, or plan to receive during the study, immune tolerance induction&#xD;
             therapy or prophylaxis with FVIII (Part A only).&#xD;
&#xD;
          4. Significant renal dysfunction or liver dysfunction, infection or history of hepatic&#xD;
             malignancy.&#xD;
&#xD;
          5. Evidence of any bleeding disorder not related to hemophilia A.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Biological males only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Specialist</last_name>
    <phone>1-800-983-4587</phone>
    <email>medinfo@bmrn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene Therapy</keyword>
  <keyword>Clotting Disorders</keyword>
  <keyword>Blood Disorder</keyword>
  <keyword>Blood Coagulation Disorders</keyword>
  <keyword>Inherited Blood Coagulation Disorders</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Coagulation Protein Disorders</keyword>
  <keyword>Hemorrhagic Disorders</keyword>
  <keyword>Genetic DIseases</keyword>
  <keyword>Factor VIII</keyword>
  <keyword>Coagulants</keyword>
  <keyword>Hemophilia A</keyword>
  <keyword>AAV5 vector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

